Evidence map›Paper›PMID 25675294›Full record

ArticleCell death & disease2015

A pro-apoptotic function of iASPP by stabilizing p300 and CBP through inhibition of BRMS1 E3 ubiquitin ligase activity.

D Kramer, M Schön, M Bayerlová, A Bleckmann, M P Schön, M Zörnig, M Dobbelstein

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Sequence variation inEMBO molecular medicine · 2017
    Article
  11. Overexpression of iASPP-SV in glioma is associated with poor prognosis by promoting cell viability and antagonizing apoptosis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016
    Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

D KramerDepartment of Molecular Oncology, University Medical Center Göttingen, Göttingen, Germany.
M SchönDepartment of Dermatology, Venereology and Allergology, University Medical Center Göttingen, Göttingen, Germany.
M BayerlováDepartment of Medical Statistics, University Medical Center Göttingen, Göttingen, Germany.
A BleckmannDepartment of Hematology and Medical Oncology, University Medical Center Göttingen, Göttingen, Germany.
M P SchönDepartment of Dermatology, Venereology and Allergology, University Medical Center Göttingen, Göttingen, Germany.
M ZörnigInstitute of Tumor Biology and Experimental Therapy, Georg Speyer Haus, Frankfurt am Main,Germany.
M DobbelsteinDepartment of Molecular Oncology, University Medical Center Göttingen, Göttingen, Germany.
Universitätsmedizin Göttingen · DEUniversity of Göttingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The p53 family and its cofactors are potent inducers of apoptosis and form a barrier to cancer. Here, we investigated the impact of the supposedly inhibitory member of the apoptosis-stimulating protein of p53, iASPP, on the activity of the p53 homolog TAp73, and its cofactors p300 and CBP. We found that iASPP interacted with and stabilized the histone acetyltransferase p300 and its homolog CBP upon cisplatin treatment. Vice versa, iASPP depletion by shRNA resulted in decreased amounts of p300 and CBP, impaired binding of p300 and TAp73 to target site promoters, reduced induction of pro-apoptotic TAp73 target genes, and impaired apoptosis. Mechanistically, we observed that the p300-regulatory E3 ubiquitin ligase BRMS1 could rescue the degradation of p300 and CBP in cisplatin-treated, iASPP-depleted cells. This argues that iASPP stabilizes p300 and CBP by interfering with their BRMS1-mediated ubiquitination, thereby contributing to apoptotic susceptibility. In line, iASPP overexpression partially abolished the interaction of BRMS1 and CBP upon DNA damage. Reduced levels of iASPP mRNA and protein as well as CBP protein were observed in human melanoma compared with normal skin tissue and benign melanocytic nevi. In line with our findings, iASPP overexpression or knockdown of BRMS1 each augmented p300/CBP levels in melanoma cell lines, thereby enhancing apoptosis upon DNA damage. Taken together, destabilization of p300/CBP by downregulation of iASPP expression levels appears to represent a molecular mechanism that contributes to chemoresistance in melanoma cells.

Indexed as

ApoptosisCell CycleChromatin ImmunoprecipitationCREB-Binding ProteinE1A-Associated p300 ProteinHEK293 CellsHumansImmunoprecipitationIntracellular Signaling Peptides and ProteinsIn Vitro TechniquesMelanomaPromoter Regions, GeneticProtein BindingRepressor ProteinsBRMS1 protein, humanCREB-Binding ProteinE1A-Associated p300 ProteinEP300 protein, humanIntracellular Signaling Peptides and ProteinsPPP1R13L protein, humanRepressor Proteins

Identifiers

PMID25675294
PMCPMC4669821
OpenAlexW2077973276

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.